Suppr超能文献

利用低剂量米诺环素(SDD)治疗牙周病的临床研究。

Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD).

机构信息

Department of Periodontology, Eastman Institute for Oral Health, University of Rochester, 625 Elmwood Avenue, Rochester, NY 14620, USA.

出版信息

Pharmacol Res. 2011 Feb;63(2):114-20. doi: 10.1016/j.phrs.2010.12.003. Epub 2010 Dec 21.

Abstract

Periodontitis, the most common chronic inflammatory condition known to mankind, is a disease that results in the destruction of tooth supporting tissues. Periodontitis is initiated by a bacterial biofilm on the tooth surface below the gingival margin. Until fairly recently it was assumed that the bacteria were the primary cause of tissue destruction, however, a large body of research has revealed that it is the patient's immune response that is actually responsible for the majority of the breakdown of tooth supporting tissues. Contemporary thinking suggests that successful, long term management of chronic periodontitis may combine both local mechanical and antimicrobial strategies to reduce the microbial bio-burden along with modulation of the host, patient's excessive, immuno-inflammatory response to the bacterial exposure known as host modulatory therapy (HMT). Based on extensive literature documenting the enzymatic inhibition and related anti-inflammatory properties of the tetracyclines, a new drug was developed as a host modulatory agent and approved by the United States Food and Drug Administration (FDA) for use as an adjunct to conventional scaling and root planing for the treatment of chronic periodontitis. A subantimicrobial dose of doxycycline (SDD) at 20 mg (Periostat(®)) has been found to be a safe and effective adjunct when taken twice daily for at least 3 months and up to 24 months in randomized placebo controlled clinical trials. Periostat(®) is currently the only FDA approved inhibitor of the matrix metalloproteinases implicated in the plaque-induced pathologic degradation of connective tissue collagen of the periodontal supporting structures. This review paper begins with a brief description of the disease process known as periodontitis followed by an extensive review of the Phase I-IV clinical trial data that established the safety and efficacy of sub-antimicrobial dose doxycycline (SDD) as an adjunct to scaling and root planing for the treatment of periodontitis.

摘要

牙周炎是人类已知的最常见的慢性炎症性疾病,是一种导致牙齿支持组织破坏的疾病。牙周炎是由牙龈缘以下牙齿表面的细菌生物膜引起的。直到最近,人们还认为细菌是导致组织破坏的主要原因,然而,大量的研究表明,实际上是患者的免疫反应导致了大部分牙齿支持组织的破坏。现代观点认为,成功的慢性牙周炎长期管理可能需要结合局部机械和抗菌策略,以减少微生物生物负荷,同时调节宿主对细菌暴露的过度免疫炎症反应,这种方法被称为宿主调节治疗(HMT)。基于大量文献记录了四环素的酶抑制作用和相关抗炎特性,一种新的药物被开发为宿主调节剂,并获得美国食品和药物管理局(FDA)的批准,作为常规牙周刮治和根面平整的辅助治疗,用于治疗慢性牙周炎。小剂量多西环素(SDD)20mg(派丽奥)每日两次,至少治疗 3 个月,最长 24 个月,在随机安慰剂对照临床试验中被发现是安全有效的辅助治疗。派丽奥是目前唯一被 FDA 批准的基质金属蛋白酶抑制剂,可抑制菌斑诱导的牙周支持组织中结缔组织胶原的病理性降解。本文首先简要描述了牙周炎的发病过程,然后对 I-IV 期临床试验数据进行了广泛回顾,这些数据证实了小剂量多西环素(SDD)作为牙周炎刮治和根面平整辅助治疗的安全性和有效性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验